Stereotactic radiation to brain metastases in patients with metastatic melanoma receiving nivolumab appeared to prolong brain metastases control and overall survival, according to a study published in the Annals of Oncology.1
Publications
Nivolumab as Single-Agent Treatment for BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.
FDA approves expanded indication for Merck’s Keytruda
The US Food and Drug Administration has approved an expanded indication for Merck’s Keytruda (pembrolizumab)…
T-VEC Approved in Europe for Unresectable Metastatic Melanoma
The European Commission has approved talimogene laherparepvec (T-VEC; Imlygic) as a treatment for adult patients with unresectable stage IIIb, IIIc, and IVM1a melanoma that has not spread to the bone, brain, lung, or other viscera, based on the phase III OPTiM study.